HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment - Wikidata - wikimedia - TriplyDB

HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment

HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment

http://www.wikidata.org/entity/Q39696123

about

Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1 The restriction factors of human immunodeficiency virus Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin BST-2/tetherin: a new component of the innate immune response to enveloped viruses Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction The role of BST-2/Tetherin in host protection and disease manifestation Host restriction factors for hepatitis C virus Structural and Biophysical Analysis of BST-2/Tetherin Ectodomains Reveals an Evolutionary Conserved Design to Inhibit Virus Release Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation Mechanism of HIV-1 virion entrapment by tetherin Counteraction of the multifunctional restriction factor tetherin Vpu and BST2: Still Not There Yet?Positioning of cysteine residues within the N-terminal portion of the BST-2/tetherin ectodomain is important for functional dimerization of BST-2.Modulation of HIV-1-host interaction: role of the Vpu accessory protein Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin.Lack of adaptation to human tetherin in HIV-1 group O and P.Animal models for HIV/AIDS research Tetherin restricts direct cell-to-cell infection of HIV-1.The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1)HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu.Association of BST-2 gene variants with HIV disease progression underscores the role of BST-2 in HIV type 1 infection.Epitope tags beside the N-terminal cytoplasmic tail of human BST-2 alter its intracellular trafficking and HIV-1 restriction Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility.Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.The HERV-K human endogenous retrovirus envelope protein antagonizes Tetherin antiviral activity The VP40 protein of Marburg virus exhibits impaired budding and increased sensitivity to human tetherin following mouse adaptation Vpu binds directly to tetherin and displaces it from nascent virions.Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis.BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action Ex vivo gene therapy for HIV-1 treatment.Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence.In COS cells Vpu can both stabilize tetherin expression and counteract its antiviral activity.Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo.

P2860

Q24297949-E022F8B7-EA17-4B85-8780-E0D89C95DA00 Q24605108-489F8B3A-C5D1-4892-B4E3-44BE2171094F Q24629504-F5D723E9-2BB4-42C6-B8A8-C483E4CEEC84 Q24630382-8B2CA33B-101B-4AB2-B514-23BC74AA9D92 Q24635271-D17A75B3-AC9B-427A-95EF-C8B769DB44EA Q26752737-DF94BAC1-208F-4A6F-9B6F-EE25D4E4D44B Q26773258-8CA407BD-D7A8-47B0-9B02-6248940FFFB6 Q27665937-A11DB2C5-8599-43E5-AF06-5B950B39ADFE Q28510187-6E6DE1D2-770A-428A-AF7E-BCEF85BB6595 Q28533773-5310E1B2-5A7E-42C8-BADA-D80DA91C53DA Q28534707-D3206B6C-E12A-458A-8383-E40B8D4205D3 Q28659945-57B5FD59-68F2-4BD1-A0ED-BDDFC42BD241 Q28730708-3B96A5B6-BFE1-4963-8B2E-53EE966E8150 Q30369981-26D3DF96-A11D-430E-A023-41994E9DB588 Q30397761-115C7E5F-39EA-4D79-A6E4-203A57CCD330 Q30406836-C6368C52-A2F8-48B0-A271-400B79C51E06 Q30407564-21996608-B477-4214-B171-F8C0FC47E73D Q30423656-09903A3D-0626-473B-B9E8-F56C5901ED6F Q30497822-96A6C716-BA01-423F-9CAE-FCCD43B0B14D Q33815533-3A55F2A6-8DA1-4A06-B17F-9A7CA5F85AB9 Q33861091-F24381D5-A585-48D0-823A-16E1D1D3AEB4 Q33887674-5E166F27-BBA6-455C-9CBB-799DBF62DDD2 Q34146128-42F2A152-77D8-42CB-8DB5-8BD5546551AA Q34311435-9DC01321-D4A0-4042-89B7-33580D59D3B6 Q34408687-EC955ABC-B530-4C55-85C9-14A42415C810 Q34416492-3A62CB9B-3AD9-48FB-AE48-D6705D2D49FA Q34426491-B61EB6D0-F527-4FDB-BECE-A8FAFC21F0E2 Q34485169-9E4FBBDB-336F-4783-B0B9-CF8D820120AA Q34505213-1DA55ABD-B911-4E63-BB63-E53CFA3685FD Q34532245-E1275F12-76E8-4393-A96C-5AFAA8F935C8 Q34594080-E770D756-1C9F-4F58-A8F4-0F397B33E14D Q34594813-85383A70-007B-449A-8ACD-786E3E14D7E7 Q34697856-5BE6F69F-153C-4FE7-BA8D-CAA736BE1BCE Q34819697-43760DE5-ED10-44D8-95F1-3DD470FF0724 Q34905536-A54526CE-277D-4D35-B2BF-50BC8D245B1F Q34982851-77D08868-F78B-43D0-BAB4-A8E0168E6F06 Q35214569-88DE9667-36D4-4B4D-9D55-7FBCC2D7E4B2 Q35382088-42D95DC5-480A-4B10-8B92-48E0E17F118C Q35383008-5007C8F4-4915-4637-AD06-659F6C325E08 Q35383070-B21081BE-B8BF-4E1C-B920-85E3C260F820

P2860

HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment

http://www.wikidata.org/entity/Q39696123

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

HIV-1 Vpu and HIV-2 Env counte ...... n in a perinuclear compartment

@en

HIV-1 Vpu and HIV-2 Env counte ...... in a perinuclear compartment.

@nl

type

label

HIV-1 Vpu and HIV-2 Env counte ...... n in a perinuclear compartment

@en

HIV-1 Vpu and HIV-2 Env counte ...... in a perinuclear compartment.

@nl

prefLabel

HIV-1 Vpu and HIV-2 Env counte ...... n in a perinuclear compartment

@en

HIV-1 Vpu and HIV-2 Env counte ...... in a perinuclear compartment.

@nl

P1433

Q39696123-4DA5AC80-637D-4857-811E-CD1CB2FA032D

P1476

Q39696123-1E14F546-EB7F-40C5-807A-13A00F768178

P2093

Q39696123-0694E3C4-1F5F-422B-BF7B-E8A3CBD237CC

Q39696123-19C8FAF8-4142-41AD-A3A8-AF2A04190B3E

Q39696123-1DB16C5C-5B13-4040-96C1-1151E90EC9DB

Q39696123-48942841-E1BF-46CE-A5FC-EAE9BAE2B29B

Q39696123-6713A371-B3E7-4D0B-9883-1F8713871762

Q39696123-855BE2F5-F32B-49C9-AA34-4B6330602927

Q39696123-DB6D1504-ED51-4393-BE23-D8421E4D4F59

P2860

Q39696123-01A8E6F6-5AEF-49AC-9ADA-56FB76FE1A21

Q39696123-0BF18F2C-8FD0-4587-82CD-E84BE313A0A7

Q39696123-0FC09ABC-B7FA-41B1-BC67-68BDC19C437C

Q39696123-18B2BC71-C982-4EC3-9EB3-2A47A5481E42

Q39696123-1D49C43C-9FD7-4D93-846F-0560170D3792

Q39696123-1FC9741B-91CD-4A43-8556-55B8BBF5DD75

Q39696123-261D491F-85A8-4FEC-870B-2C6A15A95A0C

Q39696123-28C8D2F1-BCC5-46CA-B978-E04FE142B4B9

Q39696123-2C390B3D-D145-4D5A-8D72-0508DC98C8FF

Q39696123-3001BA2F-181B-4C81-A81E-15F50330B05A

P2888

Q39696123-C46D2D46-A6FB-4EA4-BE26-03AD56D08EF2

P304

Q39696123-A6FD4240-E218-483C-A142-55CA9D3194E9

P31

Q39696123-E73793C8-CFBE-4B98-A576-9B52DADDFB5F

P356

Q39696123-C0CEE43E-C4F3-4689-894C-15943294C7C7

P478

Q39696123-0666D33D-4141-4E3D-8BE0-6FA263CEA821

P577

Q39696123-9883DEAB-4B1C-42AF-BEA7-4BA636D8E215

P5875

Q39696123-FCE850A5-27C5-47FA-B464-0D901E285247

P6179

Q39696123-BA9B15EF-6527-4D0C-B1A2-3C543C7D2264

P698

Q39696123-AFE84EFC-8D46-4FC7-9A9F-64B0F4C317A5

P921

Q39696123-A423A321-7818-4946-9715-A672E7A5491D

P932

Q39696123-B3984D13-6015-4608-BE3E-7E14E7416488

P356

P1433

P1476

HIV-1 Vpu and HIV-2 Env counte ...... n in a perinuclear compartment

@en

P2093

Colin M Exline

http://www.w3.org/2001/XMLSchema#string

Heiko Hauser

http://www.w3.org/2001/XMLSchema#string

Jill E Oldenburg

http://www.w3.org/2001/XMLSchema#string

John C Guatelli

http://www.w3.org/2001/XMLSchema#string

Lisa A Lopez

http://www.w3.org/2001/XMLSchema#string

Paula M Cannon

http://www.w3.org/2001/XMLSchema#string

Su Jung Yang

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation

Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2

Regulated degradation of the HIV-1 Vpu protein through a betaTrCP-independent pathway limits the release of viral particles

Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin

Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses

Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism

HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes

Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus

Inhibition of Lassa and Marburg virus production by tetherin

HIV accessory proteins and surviving the host cell

P2888

P304

51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1742-4690-7-51

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44655057

http://www.w3.org/2001/XMLSchema#string

P6179

1044748442

http://www.w3.org/2001/XMLSchema#string

P698

20529266

http://www.w3.org/2001/XMLSchema#string

P921

P932

2890665

http://www.w3.org/2001/XMLSchema#string